Drug Trial Radar · NCT02195700
Aim to Reduce Movements in Tardive Dyskinesia
Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
117
Actual
Start
Jun 2014
Primary completion
May 2015
Study completion May 2015
Sponsor
- Lead sponsor
- Auspex Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 21, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
Conditions
- Tardive Dyskinesia
Interventions
SD-809Drug
SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.
PlaceboDrug
Placebo tablets taken twice daily for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using Mixed Model Repeated Measures (MMRM) AnalysisTime frame: Day 0 (Baseline), Weeks 2, 4, 6, 9 and 12
Locations
41 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
Tuscaloosa, Alabama
Site not named
Anaheim, California
Site not named
Glendale, California
Site not named
Oceanside, California
Site not named
Orange, California
Site not named
San Bernardino, California
Site not named
San Diego, California
Site not named
Denver, Colorado
Site not named
New Haven, Connecticut
Site not named
Stamford, Connecticut
Site not named
Washington D.C., District of Columbia
Site not named
Boca Raton, Florida
Site not named
Gainesville, Florida
Site not named
Lake City, Florida
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
Port Charlotte, Florida
Site not named
Chicago, Illinois
Site not named
Baltimore, Maryland
Site not named
Minneapolis, Minnesota
Site not named
Kansas City, Missouri
Site not named
St Louis, Missouri
Site not named
Albuquerque, New Mexico
Site not named
Asheville, North Carolina
Site not named
Durham, North Carolina
Site not named
Raleigh, North Carolina
Site not named
Cleveland, Ohio
Site not named
Philadelphia, Pennsylvania
Site not named
Charleston, South Carolina
Site not named
Memphis, Tennessee
Site not named
Fort Worth, Texas
Site not named
Salt Lake City, Utah
Site not named
Prague, Czechia
Site not named
Gdansk, Poland
Site not named
Katowice, Poland
Site not named
Krakow, Poland
Site not named
Lodz, Poland
Site not named
Lublin, Poland
Site not named
Torun, Poland
Site not named
Domaša, Slovakia
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.